Ligand (act-4-l) to a receptor on the surface of activated...

Details Ligand (act-4-l) to a receptor on the surface of activated... Ligand (act-4-l) to a receptor on the surface of activated...

C - Chemistry, Metallurgy

12

N

C12N 15/12 (2006.01) A61K 38/17 (2006.01) A61K 39/395 (2006.01) A61P 31/18 (2006.01) C07K 7/06 (2006.01) C07K 7/08 (2006.01) C07K 14/47 (2006.01) C07K 14/73 (2006.01) C07K 16/28 (2006.01) C07K 16/46 (2006.01) C07K 19/00 (2006.01) C12N 15/13 (2006.01) C12N 15/62 (2006.01) C12P 21/02 (2006.01) G01N 33/566 (2006.01) G01N 33/567 (2006.01)

Patent

CA 2525499

The invention relates to certain specific binding partners, in particular ligands and fragments, variants, mutants or derivatives for a receptor on the surface of activated T-cells eg activated CD4+ T-cells. Exemplary ligands are based on a ligand designated ACT-4-L-h-1. Preferred fragments include extracellular domains of ligands. In addition the invention provides certain binding moieties with specificity for the above-mentioned specific binding partners. Suitable binding moieties include humanized and human antibodies to the ligand. The invention further provides nucleic acid segments which code for such a specific binding partner or biding moiety as well as expression vectors and cell lines which include these. The invention further provides pharmaceutical compositions containing the specific binding partners or the binding moieties together with methods of using the specific binding partners and binding moieties in the treatment of various diseases and conditions of the immune system. Also provided by the invention are methods of monitoring activated T-cells e.g. activated CD4+ T-cells using the specific binding partners or fragments thereof, together with kits for use in these methods.

La présente invention concerne des partenaires de liaison spécifiques, plus précisément des ligands et des fragments, des variantes, des mutants ou leurs dérivés, pour un récepteur à la surface de lymphocytes T activés, par exemple des lymphocytes T CD4+. Les ligands de l'exemple se basent sur un ligand appelé ACT-4-L-h-1. Les fragments retenus comprennent des domaines extracellulaires de ligands. L'invention concerne également certaines fractions de liaison présentant une spécificité par rapport aux partenaires de liaison spécifiques susmentionnés. Les fractions de liaison appropriées comprennent des anticorps humains et humanisés dirigés contre le ligand. L'invention concerne en outre des segments d'acide nucléique codant pour de tels partenaires de liaison ou fractions de liaison, ainsi que des vecteurs d'expression et des lignées cellulaires les incluant. L'invention concerne aussi des composés pharmaceutiques contenant lesdits partenaires de liaison ou fractions de liaison spécifiques et leurs modes d'utilisation pour le traitement de différentes maladies et affections du système immunitaire. L'invention a enfin trait à des méthodes de suivi des lymphocytes T activés, par exemple des lymphocytes T CD4+ activés à l'aide desdits partenaires de liaison spécifiques ou de leurs fragments, et aux trousses utilisées dans ces méthodes.

Affiliated with

Also associated with

Rating

Ligand (act-4-l) to a receptor on the surface of activated... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ligand (act-4-l) to a receptor on the surface of activated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ligand (act-4-l) to a receptor on the surface of activated... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1474188